Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Strong Trading Volume – Here’s Why

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares saw an uptick in trading volume on Monday. Approximately 3,150 shares changed hands during trading, an increase of 34% from the average daily volume of 2,357 shares. The stock last traded at $37.00 and had previously closed at $35.38.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ZLDPF. Barclays downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 8th. Zacks Research upgraded Zealand Pharma A/S from a “hold” rating to a “strong-buy” rating in a report on Monday, October 12th. Finally, Wells Fargo & Company reiterated an “overweight” rating on shares of Zealand Pharma A/S in a report on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, Zealand Pharma A/S presently has a consensus rating of “Hold”.

Zealand Pharma A/S Stock Down 0.3%

The business has a 50-day moving average of $39.07 and a 200-day moving average of $46.97. The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.98 and a current ratio of 13.98. The stock has a market capitalization of $2.63 billion, a price-to-earnings ratio of 6.11 and a beta of 0.99.

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company headquartered in Copenhagen, Denmark. Founded in 1998, it discovers and develops peptide-based medicines, with a focus on metabolic diseases and rare conditions. The company’s portfolio has included Zegalogue (dasiglucagon), an injectable treatment approved in the United States for severe hypoglycemia in people with diabetes. Zealand also develops investigational medicines for areas such as obesity, liver disease and rare gastrointestinal disorders, and works with pharmaceutical partners to advance and commercialize selected programs.